Please use this identifier to cite or link to this item:
|Title:||Medicinal cannabis||Authors:||Murnion, Bridin||Issue Date:||Dec-2015||Source:||Volume 38, Issue 6, pp. 212 - 215||Journal title:||Australian Prescriber||Abstract:||A number of therapeutic uses of cannabis and its derivatives have been postulated from preclinical investigations. Possible clinical indications include spasticity and pain in multiple sclerosis, cancer-associated nausea and vomiting, cancer pain and HIV neuropathy. However, evidence is limited, may reflect subjective rather than objective outcomes, and is not conclusive. Controversies lie in how to produce, supply and administer cannabinoid products. Introduction of cannabinoids therapeutically should be supported by a regulatory and educational framework that minimises the risk of harm to patients and the community. The Regulator of Medicinal Cannabis Bill 2014 is under consideration in Australia to address this. Nabiximols is the only cannabinoid on the Australian Register of Therapeutic Goods at present, although cannabidiol has been recommended for inclusion in Schedule 4.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1643||DOI:||10.18773/austprescr.2015.072||ISSN:||0312-8008||Publicaton type:||Journal Article||Keywords:||Drug Therapy|
|Appears in Collections:||Health Service Research|
Show full item record
checked on Jan 27, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.